New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms
NCT ID NCT07105111
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether valbenazine can reduce involuntary muscle movements (tardive dyskinesia) in adults who still have symptoms while taking or after stopping another similar drug. About 50 people with schizophrenia, bipolar disorder, or major depression will take valbenazine capsules for 24 weeks. Doctors and patients will report changes in movement severity and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- valbenazine
- What this could lead to
- If successful, this could offer a new treatment option for people with tardive dyskinesia whose symptoms persist despite current medications.
- What could go wrong
- This is a small, open-label study (no placebo group), so results may be less reliable. It also focuses on people who already tried another drug, so benefits may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGBryant, Arkansas, 72022, United States
-
Neurocrine Clinical Site
RECRUITINGChino, California, 91710, United States
-
Neurocrine Clinical Site
RECRUITINGFountain Valley, California, 92708, United States
-
Neurocrine Clinical Site
RECRUITINGFresno, California, 93701, United States
-
Neurocrine Clinical Site
RECRUITINGLong Beach, California, 90807, United States
-
Neurocrine Clinical Site
RECRUITINGOrange, California, 92866, United States
-
Neurocrine Clinical Site
RECRUITINGRedlands, California, 92373, United States
-
Neurocrine Clinical Site
RECRUITINGSan Diego, California, 92123, United States
-
Neurocrine Clinical Site
RECRUITINGBonita Springs, Florida, 34134, United States
-
Neurocrine Clinical Site
RECRUITINGHialeah, Florida, 33012, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33144, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33176, United States
-
Neurocrine Clinical Site
RECRUITINGOrange City, Florida, 32763, United States
-
Neurocrine Clinical Site
RECRUITINGPort Charlotte, Florida, 33980, United States
-
Neurocrine Clinical Site
RECRUITINGTampa, Florida, 33629, United States
-
Neurocrine Clinical Site
RECRUITINGAugusta, Georgia, 30912, United States
-
Neurocrine Clinical Site
RECRUITINGMarietta, Georgia, 30060, United States
-
Neurocrine Clinical Site
RECRUITINGNaperville, Illinois, 60563, United States
-
Neurocrine Clinical Site
RECRUITINGOmaha, Nebraska, 68124, United States
-
Neurocrine Clinical Site
RECRUITINGIndependence, Ohio, 44131, United States
-
Neurocrine Clinical Site
RECRUITINGAustin, Texas, 78754, United States
-
Neurocrine Clinical Site
RECRUITINGRichmond, Virginia, 23226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?